A clinical trial to study the effects of two drugs, R-TPR-026 andAranesp® in patients for correction of anemia due to Chronic Kidney Disease
- Conditions
- Patients for correction of anemia due to Chronic Kidney Disease
- Registration Number
- CTRI/2013/09/004005
- Lead Sponsor
- Reliance Life sciences Pvt Ltd
- Brief Summary
This is a prospective, multi-centre, open-label, two-arm, parallel group, active-control, randomized comparative clinical study. The present study will evaluate the efficacyxml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /
safety to evaluate efficacy and safety of R-TPR-026 and Aranesp® when given subcutaneously in patients for correction of anemia due to Chronic Kidney Disease.
The primary outcome measures will be assessed by Hemoglobin responder rate i.e., proportion of patients achieving >1 g/dL rise in Hb from baseline at Week 8. 105 subject will be recruited from 08 sites in India.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- All
- Target Recruitment
- 104
- 1 Diagnosed with anemia due to Chronic Kidney Disease (CKD) 2 On hemodialysis or peritoneal dialysis prior to enrollment in the study 3 ESA therapy naive or ESA therapy-free for at least 3 months 4 Hb < 9 g/dL based on two screening visits at least 7 days apart 5 TSAT ≥ 20% 6 Females of childbearing potential should be willing to use an approved method of double-barrier contraception and should have a negative pregnancy test.
- 7 Able to understand the study procedures, the risks involved, willing to provide written Informed Consent, and able to adhere to study schedules and requirements.
- Current severe, uncontrolled systemic disease (e.g., clinically significant hematological disease such as sickle cell anemia, myelodysplasia, hematological malignancy, hemolytic anemia, inflammatory, infectious, psychiatric or other conditions interfering with erythropoietic response) 2.
- RBC transfusion to treat anemia within 8 weeks before enrollment or scheduled to receive RBC transfusion 3.
- New York Heart Association class III or IV Congestive Heart Failure 4.
- Uncontrolled hypertension (Diastolic BP 110 mmHg or systolic BP 180 mmHg) during screening 5.
- Major surgical procedure in last 12 weeks before enrollment or anticipation of the need for major surgery during the course of study treatment 6.
- Androgen therapy within 12 weeks prior to start of study 7.
- Scheduled to receive a renal transplant 8.
- Cardiovascular disease (Acute myocardial infarction or hospitalization for CHF within 12 weeks before enrollment) 9.
- Evidence of conditions like deep vein thrombosis, cerebrovascular event (stroke or transient ischemic attack) within 12 weeks before enrollment 10.
- Uncontrolled hyper parathyroidism 1500 pg/ml during last 12 months 11.
- Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia 12.
- History of intolerance or hypersensitivity to darbepoetin alfa 13.
- Pregnant or breast-feeding women 14.
- Women of child bearing potential who are not using effective contraception during participation in the study and do not agree to do so for at least 28 days after final dose of investigational product.
- Participation in any study within 30 days before enrollment or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study 17.
- Any other condition which investigator feels would pose a significant hazard to subject if IP is administered.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary efficacy will be assessed by Hemoglobin responder rate i.e., proportion of patients achieving 1 g/dL rise in Hb from baseline at Week 8 week 8
- Secondary Outcome Measures
Name Time Method Proportion of patients achieving rise in hemoglobin i.e., 1 g/dL rise from baseline, at Week 24 week 24 Average dose of R-TPR-026/Aranesp® administered for achievement of rise of hemoglobin in the target range (9-12 g/dL) at Week 24 week 24 Proportion of patients maintaining mean Hb within target range (9-12 g/dL) at Week 24 week 24 Mean change in Hb level between the screening/baseline period and end of the study week 24 Pharmacokinetic parameters (Cmax and AUC0-168) will be calculated for single dose of R-TPR-026 and Aranesp® week 24 Pharmacodynamic parameter o Reticulocyte count assessed at Day 2 and Day 4 of Week 0, every week from Week 1 to Week 8, every alternate week from Week 10 to Week 20 and every week from Week 21 to Week 24 Evaluation of safety week 24
Trial Locations
- Locations (21)
Bharati Vidyapeeth Deemed University Medical College
🇮🇳Pune, MAHARASHTRA, India
Government Medical College, Nagpur
🇮🇳Nagpur, MAHARASHTRA, India
KEM Hospital
🇮🇳Pune, MAHARASHTRA, India
M S Ramaiah Medical College and Hospitals
🇮🇳Bangalore, KARNATAKA, India
Mandya Institute of Medical Sciences
🇮🇳Mandya, KARNATAKA, India
Manipal Hospitals
🇮🇳Bangalore, KARNATAKA, India
Maulana Azad Medical College
🇮🇳Delhi, DELHI, India
Medical College & SSG Hospital, Jail Road Vadodara
🇮🇳Vadodara, GUJARAT, India
Medipoint Hospitals Pvt. Ltd.
🇮🇳Pune, MAHARASHTRA, India
Muljibhai Patel Urological Hospital
🇮🇳Kheda, GUJARAT, India
Scroll for more (11 remaining)Bharati Vidyapeeth Deemed University Medical College🇮🇳Pune, MAHARASHTRA, IndiaDr Aditya BhabhePrincipal investigator020-24335701dr.bhabhe@gmail.com